Witnessing the stock’s movement on the chart, on Thursday, Beam Therapeutics Inc (NASDAQ: BEAM) had a quiet start as it plunged -2.79% to $33.14, before settling in for the price of $34.09 at the close. Taking a more long-term approach, BEAM posted a 52-week range of $20.84-$49.50.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 54121.88%. Meanwhile, its Annual Earning per share during the time was 5.58%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -172.38%. This publicly-traded company’s shares outstanding now amounts to $82.56 million, simultaneously with a float of $72.89 million. The organization now has a market capitalization sitting at $2.74 billion. At the time of writing, stock’s 50-day Moving Average stood at $27.18, while the 200-day Moving Average is $25.54.
Beam Therapeutics Inc (BEAM) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Beam Therapeutics Inc’s current insider ownership accounts for 11.98%, in contrast to 84.26% institutional ownership. According to the most recent insider trade that took place on Feb 18 ’25, this organization’s SVP, Finance and Treasurer sold 6,287 shares at the rate of 35.00, making the entire transaction reach 220,045 in total value, affecting insider ownership by 37,527. Preceding that transaction, on Feb 14 ’25, Company’s Chief Legal Officer sold 10,000 for 34.00, making the whole transaction’s value amount to 340,000. This particular insider is now the holder of 102,968 in total.
Beam Therapeutics Inc (BEAM) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.2 per share during the current fiscal year.
Beam Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -172.38% and is forecasted to reach -4.77 in the upcoming year.
Beam Therapeutics Inc (NASDAQ: BEAM) Trading Performance Indicators
Let’s observe the current performance indicators for Beam Therapeutics Inc (BEAM). It’s Quick Ratio in the last reported quarter now stands at 5.69. The Stock has managed to achieve an average true range (ATR) of 2.01. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 7.85.
In the same vein, BEAM’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.76, a figure that is expected to reach -1.23 in the next quarter, and analysts are predicting that it will be -4.77 at the market close of one year from today.
Technical Analysis of Beam Therapeutics Inc (BEAM)
Going through the that latest performance of [Beam Therapeutics Inc, BEAM]. Its last 5-days volume of 1.88 million indicated improvement to the volume of 1.24 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 83.06% While, its Average True Range was 2.12.
Raw Stochastic average of Beam Therapeutics Inc (BEAM) in the period of the previous 100 days is set at 85.05%, which indicates a major rise in contrast to 80.69% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 71.49% that was higher than 70.46% volatility it exhibited in the past 100-days period.
